What is Forty Seven Financial Strength?
Forty Seven has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Forty Seven's interest coverage with the available data.
As of today, Forty Seven's Altman Z-Score is 0.00.
Competitive Comparison of Forty Seven's Financial Strength
For the Biotechnology subindustry, Forty Seven's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forty Seven's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forty Seven's Financial Strength distribution charts can be found below:
* The bar in red indicates where Forty Seven's Financial Strength falls into.
Forty Seven Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Forty Seven's Interest Expense for the
months ended in Dec. 2019 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2019 was $-24.56 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2019 was $0.84 Mil.
Forty Seven's Interest Coverage for the quarter that ended in Dec. 2019 is
| GuruFocus does not calculate Forty Seven's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Forty Seven's Debt to Revenue Ratio for the quarter that ended in Dec. 2019 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Forty Seven has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forty Seven (Forty Seven) Business Description
Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
| Dennis Henner |
director |
THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
| Kristine M Ball |
director |
C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Ann D Rhoads |
officer: Chief Financial Officer |
4000 NORTH FIRST STREET, SAN JOSE CA 95134 |
| Ian T Clark |
director |
SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Jeffrey W Bird |
director |
755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005 |
| Lightspeed General Partner X, L.p. |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Lightspeed Ultimate General Partner X, Ltd. |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Jeremy Liew |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Lightspeed Venture Partners X, L.p. |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Barry Eggers |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Peter Nieh |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Ravi Mhatre |
10 percent owner |
2200 SAND HILL ROAD, MENLO PARK CA 94025 |
| Stephen A Schwarzman |
10 percent owner |
C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154 |
| Blackstone Clarus Iii L.l.c. |
10 percent owner |
C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154 |
| Blackstone Inc. |
10 percent owner |
345 PARK AVENUE, NEW YORK NY 10154 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTSV has been successfully added to your